InMode Ltd. (INMD)
Market Cap | 1.45B |
Revenue (ttm) | 423.75M |
Net Income (ttm) | 153.67M |
Shares Out | 84.62M |
EPS (ttm) | 1.84 |
PE Ratio | 9.30 |
Forward PE | 8.10 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,286,716 |
Open | 17.10 |
Previous Close | 17.19 |
Day's Range | 17.00 - 17.74 |
52-Week Range | 14.87 - 26.80 |
Beta | 2.11 |
Analysts | Buy |
Price Target | 22.60 (+32.32%) |
Earnings Date | Feb 11, 2025 |
About INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. It also des... [Read more]
Financial Performance
In 2023, InMode's revenue was $492.05 million, an increase of 8.32% compared to the previous year's $454.27 million. Earnings were $197.92 million, an increase of 22.54%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for INMD stock is "Buy." The 12-month stock price forecast is $22.6, which is an increase of 32.32% from the latest price.
News
InMode: Product Origination And Undervaluation Make The Stock A Buy
InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative tec...
InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel , Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor con...
InMode: $25/Share Is Closer Than You Think
Elevated interest rates continue to hurt InMode's revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy ...
InMode: A Deep Dive After Q3 Earnings
InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share pr...
InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript
InMode Ltd. (NASDAQ:INMD) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Te...
InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results f...
InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories
IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd.
InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Confer...
Stock Picks From Seeking Alpha's September 2024 New Analysts
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and...
InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy
YOKNEAM, Israel , Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of No...
InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
InMode's Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slo...
InMode Announces Share Repurchase Program of Up to 7.68 Million Shares
YOKNEAM, Israel , Sept. 10, 2024 /PRNewswire/ -- InMode Ltd.
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling h...
InMode to Present at 2024 Baird Global Healthcare Conference
YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd.
InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:07 AM ET InMode Ltd. (NASDAQ:INMD) Q2 2024 Earnings Conference Call August 01, 2024, 08:30 AM ET Company Participants Moshe Mizrahy - CEO Michael Kreindel - Co-Fou...
InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results fo...
InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform
IRVINE, Calif. , July 31, 2024 /PRNewswire/ -- InMode Ltd.
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI , July 25, 2...
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd.
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursd...
InMode: Reversing Previous Shareholder Dilution With Buybacks
Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals,...
InMode to Present at Jefferies Healthcare Conference
YOKNEAM, Israel , May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Sp...
InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand
IRVINE, Calif. , May 8, 2024 /PRNewswire/ -- InMode Ltd.
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("I...
IMPORTANT DEADLINE TODAY: The Schall Law Firm Encourages Investors in InMode Ltd. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against InMode Ltd. ("InMode" or "the Co...